ROYAL PHARM -A (RPRX)
$33.69
0.06 (0.18%)
RPRX Stock Quote Delayed 30 Minutes
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$33.70
Market Cap
19.46B
PE Ratio
23.30
EPS
1.4458
Volume (Avg. Vol.)
2.30M
Day's Range
$33.60 - $33.99
52-Week Range
$23.87 - $34.20
Dividend & Yield
$0.85 (2.52%)
RPRX Stock Predictions, Articles, and ROYAL PHARM -A News
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, trader! Start your day off the right way with a breakdown of the biggest pre-market stock movers for Tuesday.
Royalty Pharma Stock Should Be Moving Off Your Watchlist
Royalty Pharma stock has faded after rallying immediately after its IPO. With valuation more reasonable, RPRX has a solid long-term case.
Royalty Pharma Is the Left-Field Investment You’re Missing Out On
You'll have a rare chance to capitalize on two highly lucrative markets as Royalty Pharma stock profits from drugmakers in a different way.
Royalty Pharma’s Cash Flow Growth Will Power the Stock Higher
Royalty Pharma's cash flow growth will power the stock higher. If cash flow continues at this pace, RPRX stock could rise by at least 88% over the next three years.
RPRX Will Have a Low Yield Until the Lock-Up Ends
Potential Royalty Pharma investors should wait until well after the lock-up period expires to buy RPRX stock.
Royalty Pharma Stock Is Likely to Reach New Highs in the Coming Years
Recent IPO by Royalty Pharma which acquires ownership interests in drug royalties is getting a lot of interest on Wall Street. Long-term investors may want to keep a close eye on RPRX stock
Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO
An innovative model and a diversified base make Royalty Pharma stock interesting, particularly if a recent pullback continues
Royalty Pharma IPO: 15 Things for Potential RPRX Stock Investors to Know
The Royalty Pharma (RPRX) IPO is currently underway and 'InvestorPlace' has everything investors need to know about the offering.
Biggest Movers in Manufacturing Stocks Now – STRT RPRX RETA SUPN
The following stocks were moving the Manufacturing sector today.
6 Pharmaceuticals Stocks to Buy Now
The grades of 6 Pharmaceuticals stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
